We evaluated the interferon-free combination of the protease inhibitor ABT-@ with ritonavir ( ABT-@ / r ) , the NS@A inhibitor ombitasvir ( ABT-@ ) , the nonnucleoside polymerase inhibitor dasabuvir ( ABT-@ ) , and ribavirin in an open-label phase @ trial involving previously untreated and previously treated adults with HCV genotype @ infection and compensated cirrhosis .